glp 1 new indications GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits KDIGO 2026: Glucagon-like peptide-1-based therapies

Most notable is a study of cardiovascular outcomes among 2,287 patients with type 2 diabetes and obesity who underwent bariatric surgery at Cleveland Clinic and 11,435 matched controls ( JAMA

High-Protein & Low-Calorie With a carefully crafted formula, this shake delivers a high-protein boost while keeping calories low, making it a great choice for anyone managing their diet and looking for a smart alternative to traditional high-calorie drinks

Yes, PlexusDx compounded semaglutide from licensed 503A pharmacies qualifies as an FSA-eligible medical expense when prescribed by a physician for a documented condition like obesity, diabetes, or prediabetes

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

These plans are designed to address the root cause of each patients condition and promote long-term health and wellness